Evidence for involvement of endogenous somatostatin in the galanin-induced growth hormone secretion in children

What Was Tested

The paper reports a study of Somatostatin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

The researchers have evaluated the effects of the combined administration of Galanin (Gal) plus growth hormone-releasing hormone (GHRH) and of pyridostigmine (PD), a cholinergic agonist, plus Gal on GH secretion in 15 children (12 males and three females, age 7.7-14.5 y) with short stature.

Children were subdivided into two groups.

Who Took Part

The abstract describes 15 children taking part.

The age groups tagged for this paper are children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

What Was Measured

The researchers have evaluated the effects of the combined administration of Galanin (Gal) plus growth hormone-releasing hormone (GHRH) and of pyridostigmine (PD), a cholinergic agonist, plus Gal on GH secretion in 15 children (12 males and three females, age 7.7-14.5 y) with short stature.

The subject headings attached to it are Drug Synergism, Galanin, Growth Disorders, Growth Hormone, Growth Hormone-Releasing Hormone, Peptides and Pyridostigmine Bromide.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and GHRH (Growth Hormone-Releasing Hormone) in 15 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Pediatric research), a journal based in United States.

More context: the Somatostatin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.